BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BMRN
-0.45 (-0.47%)
Real-time:   1:59PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 95.22 - 96.61
52 week 62.12 - 136.85
Open 95.75
Vol / Avg. 338,319.00/1.93M
Mkt cap 16.19B
P/E     -
Div/yield     -
EPS -3.27
Shares 170.78M
Beta 1.13
Inst. own 99%
Oct 27, 2016
Q3 2016 Biomarin Pharmaceutical Inc Earnings Release (Estimated) Add to calendar
Sep 8, 2016
Biomarin Pharmaceutical Inc at Robert W Baird Global Healthcare Conference - 9:40AM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Biomarin Pharmaceutical Inc Earnings Call and business update
Aug 4, 2016
Q2 2016 Biomarin Pharmaceutical Inc Earnings Release
Jul 27, 2016
Biomarin Pharmaceutical Inc interim results of an open-label Phase 1/2 study of BMN 270, an AAV5-FVIII Corporate Call
Jun 9, 2016
Biomarin Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference
Jun 8, 2016
Biomarin Pharmaceutical Inc Annual Shareholders Meeting (Estimated)
Jun 6, 2016
Biomarin Pharmaceutical Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -141.12% -19.31%
Operating margin -190.85% -12.46%
EBITD margin - -25.21%
Return on average assets -50.31% -5.54%
Return on average equity -80.75% -8.75%
Employees 2,158 -
CDP Score - -


105 Digital Dr
NOVATO, CA 94949-8703
United States - Map
+1-415-5066700 (Phone)
+1-415-3827889 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

Officers and directors

Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel Keith Spiegelman Chief Financial Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
G. Eric Davis Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 61
Bio & Compensation  - Reuters
Henry J. Fuchs M.D.,Ph.D. Executive Vice President and Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller, Chief Accounting Officer
Age: 42
Bio & Compensation  - Reuters
Richard A. Meier Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
Willard H. Dere M.D. Director
Age: 62
Bio & Compensation  - Reuters
Kathryn E. Falberg Director
Age: 55
Bio & Compensation  - Reuters